Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity

• Published in: Cancer research (Chicago, Ill.) Vol. 55; no. 5; pp. 1176 - 1180
• Main Authors: BOUSQUET, P. F, BRANA, M. F, KEILHAUER, G, ROMERDAHL, C. A, CONLON, D, FITZGERALD, K. M, PERRON, D, COCCHIARO, C, MILLER, R, MORAN, M, GEORGE, J, XIAO-DONG QIAN
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.03.1995
• Subjects: Amides - pharmacology; Animals; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Breast Neoplasms - drug therapy; Chemotherapy; Colonic Neoplasms - drug therapy; Drug Screening Assays, Antitumor; Female; Humans; Isoquinolines - pharmacology; Lung Neoplasms - drug therapy; Medical sciences; Melanoma - drug therapy; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms - drug therapy; Ovarian Neoplasms - drug therapy; Pharmacology. Drug treatments; Topoisomerase II Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured - drug effects; Antineoplastic agent; Human; Intercalating agent; Rodentia; Preclinical trial; Cytotoxicity; Malignant tumor; Heterotransplantation; In vitro; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Animal; Established cell line; Tumor cell
• ISSN: 0008-5472; 1538-7445

LU 79553 is a novel bis-naphthalimide which is highly cytotoxic in vitro with EC50 (concentration required for 50% inhibition of growth) ranging from 2 x 10(-7) to 5 x 10(-10) M. A number of studies were conducted to examine its antitumor activity in human xenograft models. In addition, we wanted to explore the possible schedule dependency of LU 79553 cytotoxicity in these xenograft models. Complete regression of MX-1 (mammary carcinoma) xenografts was observed when LU 79553 was administered i.v. daily for 5 doses at 20 mg/kg (2 cycles starting on Days 6 and 20) or every 3 days for 2 doses at 55 mg/kg (2 cycles starting on Days 6 and 13) or every 7 days for 4 doses. Complete regression was also seen in the MX-1 model when tumors were staged at 1-2 g prior to the initiation of treatment. Regressions (complete or partial) were observed in the LX-1 (lung), CX-1 (colon), DLD (colon), and LOX (melanoma) xenograft models. A significant increase in the median survival time of OVCAR-3- (ovarian carcinoma) bearing mice was noted in LU 79553-treated animals (treated/control = 195%). The excellent activity of this compound in such a wide variety of tumor types suggests LU 79553 merits further investigation in clinical trials.